1
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Sasako M, Sano T, Yamamoto S, Kurokawa Y,
Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai
K, et al: D2 lymphadenectomy alone or with para-aortic nodal
dissection for gastric cancer. N Engl J Med. 359:453–462. 2008.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wang LB, Teng RY, Jiang ZN, Hu WX, Dong
MJ, Yuan XM, Chen WJ, Jin M and Shen JG: Clinicopathologic
variables predicting tumor response to neoadjuvant chemotherapy in
patients with locally advanced gastric cancer. J Surg Oncol.
105:293–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Carlomagno C, Pepe S, D'Armiento FP,
D'Armiento M, Cannella L, De Stefano A, Crispo A, Giordano M and De
Placido S: Predictive factors of complete response to neoadjuvant
chemoradiotherapy in patients with rectal cancer. Oncology.
78:369–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Langer R, Ott K, Feith M, Lordick F,
Siewert JR and Becker K: Prognostic significance of
histopathological tumor regression after neoadjuvant chemotherapy
in esophageal adenocarcinomas. Mod Pathol. 22:1555–1563. 2009.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Suárez J, Vera R, Balén E, Gómez M, Arias
F, Lera JM, Herrera J and Zazpe C: Pathologic response assessed by
mandard grade is a better prognostic factor than down staging for
disease-free survival after preoperative radiochemotherapy for
advanced rectal cancer. Colorectal Dis. 10:563–568. 2008.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Smith FM, Reynolds JV, Kay EW, Crotty P,
Murphy JO, Hollywood D, Gaffney EF, Stephens RB and Kennedy MJ:
COX-2 overexpression in pretreatment biopsies predicts response of
rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol
Biol Phys. 64:466–472. 2006. View Article : Google Scholar : PubMed/NCBI
|
11
|
Novell A, Morales S, Valls J, Panadés MJ,
Salud A, Iglesias E, Vilardell F, Matias-Guiu X and Llombart-Cussac
A: Novel biomarkers in primary breast core biopsies to predict poor
response to neoadjuvant chemotherapy and appearance of metastases.
Histol Histopathol. 32:909–915. 2017.PubMed/NCBI
|
12
|
Barski OA, Tipparaju SM and Bhatnagar A:
The aldo-keto reductase superfamily and its role in drug metabolism
and detoxification. Drug Metab Rev. 40:553–624. 2008. View Article : Google Scholar : PubMed/NCBI
|
13
|
Yan R, Zu X, Ma J, Liu Z, Adeyanju M and
Cao D: Aldo-keto reductase family 1 B10 gene silencing results in
growth inhibition of colorectal cancer cells: Implication for
cancer intervention. Int J Cancer. 121:2301–2306. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Crosas B, Hyndman DJ, Gallego O, Martras
S, Parés X, Flynn TG and Farrés J: Human aldose reductase and human
small intestine aldose reductase are efficient retinal reductases:
Consequences for retinoid metabolism. Biochem J. 373:973–979. 2003.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Wang C, Yan R, Luo D, Watabe K, Liao DF
and Cao D: Aldo-keto reductase family 1 member B10 promotes cell
survival by regulating lipid synthesis and eliminating carbonyls. J
Biol Chem. 284:26742–26748. 2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Hyndman DJ and Flynn TG: Sequence and
expression levels in human tissues of a new member of the aldo-keto
reductase family. Biochim Biophys Acta. 1399:198–202. 1998.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Heringlake S, Hofdmann M, Fiebeler A,
Manns MP, Schmiegel W and Tannapfel A: Identification and
expression analysis of the aldo-ketoreductase1-B10 gene in primary
malignant liver tumours. J Hepatol. 52:220–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Fukumoto S, Yamauchi N, Moriguchi H, Hippo
Y, Watanabe A, Shibahara J, Taniguchi H, Ishikawa S, Ito H,
Yamamoto S, et al: Overexpression of the aldo-keto reductase family
protein AKR1B10 is highly correlated with smokers' non-small cell
lung carcinomas. Clin Cancer Res. 11:1776–1785. 2005. View Article : Google Scholar : PubMed/NCBI
|
19
|
Ma J, Luo DX, Huang C, Shen Y, Bu Y,
Markwell S, Gao J, Liu J, Zu X, Cao Z, et al: AKR1B10
overexpression in breast cancer: Association with tumor size, lymph
node metastasis and patient survival and its potential as a novel
serum marker. Int J Cancer. 131:E862–E871. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Chung YT, Matkowskyj KA, Li H, Bai H,
Zhang W, Tsao MS, Liao J and Yang GY: Overexpression and oncogenic
function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic
carcinoma. Mod Pathol. 25:758–766. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Laffin B and Petrash JM: Expression of the
aldo-ketoreductases AKR1B1 and AKR1B10 in human cancers. Front
Pharmacol. 3:1042012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Luo L, Chen Y, Wu D, Shou J, Wang S, Ye J,
Tang X and Wang Jun X: Differential expression patterns of Nqo1,
AKR1B8 and Ho-1 in the liver and small intestine of C57BL/6 mice
treated with sulforaphane. Data Brief. 5:416–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Luo L, Chen Y, Wu D, Shou J, Wang S, Ye J,
Tang X and Wang XJ: Butylated hydroxyanisole induces distinct
expression patterns of Nrf2 and detoxification enzymes in the liver
and small intestine of C57BL/6 mice. Toxicol Appl Pharmacol.
288:339–348. 2015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ahmed SM, Wu X, Jin X, Zhang X, Togo Y,
Suzuki T, Li Y, Kanematsu A, Nojima M, Yamamoto S, et al:
Synergistic induction of apoptosis by mapatumumab and
anthracyclines in human bladder cancer cells. Oncol Rep.
33:566–572. 2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Tang X, Wang H, Fan L, Wu X, Xin A, Ren H
and Wang XJ: Luteolin inhibits Nrf2 leading to negative regulation
of the Nrf2/ARE pathway and sensitization of human lung carcinoma
A549 cells to therapeutic drugs. Free Radic Biol Med. 50:1599–1609.
2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
27
|
Singletary SE, Allred C, Ashley P, Bassett
LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et
al: Staging system for breast cancer: Revisions for the 6th edition
of the ajcc cancer staging manual. Surg Clin North Am. 83:803–819.
2003. View Article : Google Scholar : PubMed/NCBI
|
28
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
29
|
Mandard AM, Dalibard F, Mandard JC, Marnay
J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P and Samama
G: Pathologic assessment of tumor regression after preoperative
chemoradiotherapy of esophageal carcinoma. Clinicopathologic
correlations. Cancer. 73:2680–2686. 1994. View Article : Google Scholar : PubMed/NCBI
|
30
|
Kawasaki Y, Ishigami S, Arigami T,
Uenosono Y, Yanagita S, Uchikado Y, Kita Y, Nishizono Y, Okumura H,
Nakajo A, et al: Clinicopathological significance of nuclear factor
(erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer.
BMC Cancer. 15:52015. View Article : Google Scholar : PubMed/NCBI
|
31
|
Yao HB, Xu Y, Chen LG, Guan TP, Ma YY, He
XJ, Xia YJ, Tao HQ and Shao QS: AKR1B10, a good prognostic
indicator in gastric cancer. Eur J Surg Oncol. 40:318–324. 2014.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Wang LB, Shen JG, Xu CY, Chen WJ, Song XY
and Yuan XM: Neoadjuvant chemotherapy versus surgery alone for
locally advanced gastric cancer: A retrospective comparative study.
Hepatogastroenterology. 55:1895–1898. 2008.PubMed/NCBI
|
33
|
Mallery S, DeCamp M, Bueno R, Mentzer SJ,
Sugarbaker DJ, Swanson SJ and Van Dam J: Pretreatment staging by
endoscopic ultrasonography does not predict complete response to
neoadjuvant chemoradiation in patients with esophageal carcinoma.
Cancer. 86:764–769. 1999. View Article : Google Scholar : PubMed/NCBI
|
34
|
Brown WA, Thomas J, Gotley D, Burmeister
BH, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA and
Smithers BM: Use of oesophagogastroscopy to assess the response of
oesophageal carcinoma to neoadjuvant therapy. Br J Surg.
91:199–204. 2004. View
Article : Google Scholar : PubMed/NCBI
|
35
|
Biondo S, Navarro M, Marti-Rague J,
Arriola E, Pares D, Del Rio C, Cambray M and Novell V: Response to
neoadjuvant therapy for rectal cancer: Influence on long-term
results. Colorectal Dis. 7:472–479. 2005. View Article : Google Scholar : PubMed/NCBI
|
36
|
Yao HB, Xu Y, Chen LG, Guan TP, Ma YY, Tao
HQ and Shao QS: Expression of aldo-keto reductase family 1 member
B10 in gastric cancer tissues and its clinical significance.
Zhonghua Wei Chang Wai Ke Za Zhi. 16:183–187. 2013.(In Chinese).
PubMed/NCBI
|
37
|
Jacobs AT and Marnett LJ: Systems analysis
of protein modification and cellular responses induced by
electrophile stress. Acc Chem Res. 43:673–683. 2010. View Article : Google Scholar : PubMed/NCBI
|
38
|
LoPachin RM, Gavin T, Petersen DR and
Barber DS: Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein
toxicity: Nucleophilic targets and adduct formation. Chem Res
Toxicol. 22:1499–1508. 2009. View Article : Google Scholar : PubMed/NCBI
|
39
|
Zhong L, Liu Z, Yan R, Johnson S, Zhao Y,
Fang X and Cao D: Aldo-keto reductase family 1 B10 protein
detoxifies dietary and lipid-derived alpha, beta-unsaturated
carbonyls at physiological levels. Biochem Biophys Res Commun.
387:245–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
40
|
Luo DX, Huang MC, Ma J, Gao Z, Liao DF and
Cao D: Aldo-keto reductase family 1, member B10 is secreted through
a lysosome-mediated non-classical pathway. Biochem J. 438:71–80.
2011. View Article : Google Scholar : PubMed/NCBI
|
41
|
Matsunaga T, Wada Y, Endo S, Soda M,
El-Kabbani O and Hara A: Aldo-keto reductase 1B10 and its role in
proliferation capacity of drug-resistant cancers. Front Pharmacol.
3:52012. View Article : Google Scholar : PubMed/NCBI
|
42
|
Liu Z, Zhong L, Krishack PA, Robbins S,
Cao JX, Zhao Y, Chung S and Cao D: Structure and promoter
characterization of aldo-keto reductase family 1 B10 gene. Gene.
437:39–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
43
|
Nishinaka T, Miura T, Okumura M, Nakao F,
Nakamura H and Terada T: Regulation of aldo-keto reductase AKR1B10
gene expression: Involvement of transcription factor Nrf2. Chem
Biol Interact. 191:185–191. 2011. View Article : Google Scholar : PubMed/NCBI
|